Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-14), M1 Kliniken AG's 1-Year Sharpe Ratio is -68.43.
M1 Kliniken AG (OTCPK:MKLNF) 1-Year Sharpe Ratio Explanation
The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
M1 Kliniken AG 1-Year Sharpe Ratio Related Terms
MKLNF vs MCK, COR, CAH: 1-Year Sharpe Ratio Comparison
For the Medical Distribution subindustry, M1 Kliniken AG's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
M1 Kliniken AG 1-Year Sharpe Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, M1 Kliniken AG's 1-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where M1 Kliniken AG's 1-Year Sharpe Ratio falls into.
The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.
M1 Kliniken AG (MKLNF) has a 1-Year Sharpe Ratio of -68.43 as of Aug. 14, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for M1 Kliniken AG and its competitors.
Is M1 Kliniken AG's 1-Year Sharpe Ratio too high?
M1 Kliniken AG's current 1-Year Sharpe Ratio is -68.43. Overall, M1 Kliniken AG has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does M1 Kliniken AG's 1-Year Sharpe Ratio compare to MCK and COR?
M1 Kliniken AG's 1-Year Sharpe Ratio of -68.43 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Distribution company?
A good 1-Year Sharpe Ratio depends on the Medical Distribution industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for M1 Kliniken AG and its competitors. M1 Kliniken AG's current 1-Year Sharpe Ratio is -68.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is M1 Kliniken AG stock overvalued right now?
M1 Kliniken AG (MKLNF) has a current 1-Year Sharpe Ratio of -68.43. The stock's GF Value™ is $9.78, compared to a current price of $11.73 — trading 19.9% above its estimated fair value. The current 1-Year Sharpe Ratio is -68.43. M1 Kliniken AG's overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For M1 Kliniken AG (MKLNF), the current 1-Year Sharpe Ratio is -68.43 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is M1 Kliniken AG (MKLNF) Overvalued in 2026?
Based on GuruFocus' analysis, M1 Kliniken AG stock appears to be overvalued.
The current stock price of $11.73 is trading 19.9% above its estimated GF Value™ of $9.78.
Key valuation signals for MKLNF:
1-Year Sharpe Ratio: -68.43
GF Value™: $9.78 vs. price of $11.73 (19.9% above fair value)
No single metric tells the full story. See the MKLNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
M1 Kliniken AG operates in the growing market of aesthetic medicine and plastic surgery and provides aesthetic medical treatments in the self-pay segment. It operates through Beauty and Trade segments. Its activities are focused on providing aesthetic medical treatment. In addition to medical aesthetic treatments, the company also develops and markets pharmaceutical, medical, and medical technology products for aesthetic surgery and cosmetic dermatology. Some of the treatments offered by the group are lip under injection, eyebrow lift, tummy tuck, breast reduction, sweat treatment, liposuction, and others. The organization conducts its business operations in Germany. The majority of its revenue is derived from the Trade segment.
92GF Score
Get the complete analysis for MKLNF
1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MKLNF has been successfully added to your 
